7 completed, 4 recruiting, 4 unknown, 2 not yet recruiting. 6 Not applicable, 6 Phase 3, 5 Phase 2, 1 Phase 1.
Follow Neoadjuvant Chemoradiotherapy: new trials by email Literature Review of Neoadjuvant Chemoradiotherapy trials Research Report on Neoadjuvant Chemoradiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy Neoadjuvant therapy with PD-L1 inhibitor - Esophageal Cancer | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 600 | 2025-04-01 | 2025-03-21 | |
| NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC Neoadjuvant Chemoradiotherapy, neoadjuvant immunotherapy, Surgery - Esophageal Squamous Cell Carcinoma (ESCC) | Not applicable | Active not recruiting | RenJi Hospital | 50 | 2024-10-30 | 2025-01-07 |
| Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer Neoadjuvant Chemoradiotherapy, Total Neoadjuvant Therapy - Rectal Cancer | Phase 3 | Not yet recruiting | St. James's Hospital, Ireland | 100 | 2024-10-01 | 2023-10-25 |
| Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma Cardonilizumab, Paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Tongji Hospital | 336 | 2024-01-29 | 2026-07-13 |
| Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial Neoadjuvant Chemoradiotherapy, Adjuvant Chemotherapy, Consolidation Chemotherapy - Rectal Neoplasms | Not applicable | Recruiting | Larissa University Hospital | 84 | 2022-08-30 | 2026-08-26 |
| Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC Neoadjuvant Chemoradiotherapy, Tislelizumab, Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended) - Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III | Phase 2 / Phase 3 | Recruiting | Shanghai Zhongshan Hospital | 176 | 2022-03-02 | 2022-06-30 |
| Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) Pembrolizumab, Paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 342 | 2021-12-01 | 2022-06-01 |
| Long Term Bowel Function Following Rectal Cancer Surgery chemoradiotherapy - Bowel; Functional Syndrome, Rectal Cancer | Not applicable | Completed | Mansoura University | 171 | 2019-08-12 | 2022-04-21 |
| Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study) Neoadjuvant chemoradiotherapy, Oesophagectomy, Neoadjuvant chemotherapy - Radiotherapy Side Effect, Chemotherapy Effect | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 423 | 2018-11-14 | 2020-05-29 | |
| Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC Neoadjuvant immunochemotherapy, Neoadjuvant Chemoradiotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Not applicable | Completed | Yongtao Han | 200 | 2018-03-01 | 2025-11-19 |
| Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC Neoadjuvant Chemoradiotherapy, Adjuvant therapy, Surgery - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Completed | Yongtao Han | 254 | 2018-01-01 | 2025-01-15 |
| Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC Neoadjuvant Chemoradiotherapy, Neoadjuvant Chemotherapy, Minimally Invasive Esophagectomy - Esophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0 | Not applicable | Completed | Shanghai Zhongshan Hospital | 264 | 2017-01-01 | 2020-09-10 |
| Surgery Without Neoadjuvant Chemoradiotherapy Compared With Neoadjuvant Chemoradiotherapy for Rectal Cancer With Negative Circumferential Resection Margin Based on MRI Assessment, a Perspective Multicenter Randomized Controlled Trial neoadjuvant chemoradiotherapy - Circumferential Resection Margin, Intraoperative Perforation of Rectum | Not applicable | Unknown | Beijing Chao Yang Hospital | 350 | 2016-12-01 | 2021-02-08 |
| Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer Neoadjuvant Chemoradiotherapy, Neoadjuvant Chemotherapy, R0 D2 Gastrectomy - Gastric Cancer | Phase 3 | Completed | Sun Yat-sen University | 620 | 2013-06-01 | 2025-07-03 |
| Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection Neoadjuvant Chemoradiotherapy - Non-small Cell Lung Cancer Stage IIIA | Phase 2 | Unknown | Zhejiang Cancer Hospital | 75 | 2013-03-01 | 2013-08-21 |
| Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer Neoadjuvant chemoradiotherapy, Adjuvant chemoradiotherapy - Esophageal Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 60 | 2011-10-01 | 2013-05-14 |
| Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases neoadjuvant chemoradiotherapy - Non-small Cell Lung Cancer | Phase 2 | Unknown | Shanghai Jiao Tong University School of Medicine | 80 | 2010-08-01 | 2010-08-24 |
| Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma epirubicin hydrochloride, ifosfamide, sorafenib tosylate - Sarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 18 | 2009-02-01 | 2018-09-07 |
| RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus transthoracic esophagectomy 2-field extended lymphadenectomy, neoadjuvant chemotherapy (cisplatin, 5-fluorouracil), neoadjuvant chemoradiotherapy - Esophageal Neoplasms, Squamous Cell Cancer | Phase 3 | Terminated | Ministry of Scientific Research and Information Technology, Poland | 84 | 2001-12-01 | 2007-11-16 |
Esophageal Squamous Cell Carcinoma (7) · Esophageal Neoplasms (4) · Rectal Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Irritable Bowel Syndrome (1) · Neoplasms (1) · Neoplasms, Squamous Cell (1) · Pathologic Complete Response (1) · Radiation Injuries (1) · Recurrence (1) · Sarcoma (1) · Stomach Neoplasms (1)
Shanghai Zhongshan Hospital (2) · Yongtao Han (2) · Zhejiang Cancer Hospital (2) · Beijing Chao Yang Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Larissa University Hospital (1) · Mansoura University (1) · Ministry of Scientific Research and Information Technology, Poland (1) · OHSU Knight Cancer Institute (1) · RenJi Hospital (1) · Shanghai Jiao Tong University School of Medicine (1) · St. James's Hospital, Ireland (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Sun Yat-sen University (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (13) · United States (2) · Egypt (1) · Greece (1) · Poland (1)
Lijie Tan, MD (2) · Weimin Mao, MD (2) · Christopher W. Ryan, MD (1) · George Tzovaras, Prof (1) · Grzegorz Wallner, MD, PhD (1) · Haiyu Zhou, PhD (1) · Herui Yao, PhD (1) · Konstantinos Perivoliotis, MD (1) · Michael Lanuti, PhD (1) · Zhi-wei Zhou, M.D, Ph.D (1)
PMID 14530720, PMID 18320278, PMID 19770374, PMID 20857337, PMID 21084184, PMID 21296855, PMID 21444866, PMID 21684205, PMID 22552194, PMID 24211053, PMID 24266955, PMID 24493117, PMID 24847029, PMID 24876941, PMID 24982463, PMID 25038015, PMID 25180663, PMID 25249141, PMID 25691613, PMID 26254683, PMID 26808342, PMID 28659128, PMID 32637899, PMID 33729467, PMID 35433421, PMID 36400384, PMID 41490111
P30CA069533 (1)